申联生物(688098.SH)：UBI拟减持不超3%股份

Core Viewpoint - Shenyuan Biological (688098.SH) announced a plan for United Biomedical, Inc. (UBI) to reduce its shareholding in the company to fund clinical trials and commercialization of its Alzheimer's synthetic peptide vaccine and related manufacturing base in China [1] Group 1 - UBI plans to reduce its shareholding by selling 4.1064 million shares through centralized bidding on the Shanghai Stock Exchange, which represents no more than 1% of the company's total shares [1] - Additionally, UBI intends to sell 8.2129 million shares through block trading, accounting for no more than 2% of the company's total shares [1] - The share reduction will occur within three months following the announcement, starting 15 trading days after the disclosure [1]